Stock comparison
Moderna, Inc. is 7.0x more valuable than Denali Therapeutics Inc. by market capitalization ($30.38 B vs $4.32 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
MRNA is larger
Moderna, Inc. is 7.0x more valuable than Denali Therapeutics Inc. by market capitalization ($30.38 B vs $4.32 B).
Market value leader
MRNA
Moderna, Inc. is 7.0x more valuable than Denali Therapeutics Inc. by market capitalization ($30.38 B vs $4.32 B).
Revenue leader
MRNA
DNLI: $0.00 vs MRNA: $1.94B.
Profit leader
DNLI
DNLI: -$512.54M vs MRNA: -$2.82B.
| Metric | DNLI | MRNA |
|---|---|---|
| Market cap | $4.32 B | $30.38 B |
| US-listed rank | #1534 | #461 |
| Revenue (latest FY) | $0.00 | $1.94B |
| Net income (latest FY) | -$512.54M | -$2.82B |
| Net margin | - | -145.2% |
| P/E (trailing FY) | - | - |
| SEC filings | 763 | 1,447 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Moderna, Inc. is 7.0x more valuable than Denali Therapeutics Inc. by market capitalization ($30.38 B vs $4.32 B).
In their latest fiscal years, Denali Therapeutics Inc. reported $0.00 in revenue while Moderna, Inc. reported $1.94B.
Full pages: Denali Therapeutics Inc. and Moderna, Inc., or browse the full rankings.